Tumor Evolution Analysis Uncovered Immune-escape Related Mutations in Relapse of Diffuse Large B-cell Lymphoma

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2024 Jul 30

PMID 39080353

Authors

Xueshuai Han

Jingru Sui

Kui Nie

Yang Zhao

Xuan Lv

Jindou Xie

Leonard Tan

Rex K H Au-Yeung

Jiao Ma

Giorgio Inghirami

Olivier Elemento

Wayne Tam

Zhaoqi Liu

Affiliations

Soon will be listed here.

References

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(4):235-42. DOI: 10.1056/NEJMoa011795. View

Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K . CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006; 7(5):379-91. DOI: 10.1016/S1470-2045(06)70664-7. View

Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E . Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008; 9(2):105-16. DOI: 10.1016/S1470-2045(08)70002-0. View

Maurer M, Ghesquieres H, Jais J, Witzig T, Haioun C, Thompson C . Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014; 32(10):1066-73. PMC: 3965261. DOI: 10.1200/JCO.2013.51.5866. View

Berendsen M, Stevens W, Brand M, van Krieken J, Scheijen B . Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy Resistance. Cancers (Basel). 2020; 12(12). PMC: 7760867. DOI: 10.3390/cancers12123553. View

Schmitz R, Wright G, Huang D, Johnson C, Phelan J, Wang J . Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018; 378(15):1396-1407. PMC: 6010183. DOI: 10.1056/NEJMoa1801445. View

Sun X, Frierson H, Chen C, Li C, Ran Q, Otto K . Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat Genet. 2005; 37(4):407-12. DOI: 10.1038/ng1528. View

Youssef I, Ricort J . Deciphering the Role of Protein Kinase D1 (PKD1) in Cellular Proliferation. Mol Cancer Res. 2019; 17(10):1961-1974. DOI: 10.1158/1541-7786.MCR-19-0125. View

Chapuy B, Stewart C, Dunford A, Kim J, Kamburov A, Redd R . Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018; 24(5):679-690. PMC: 6613387. DOI: 10.1038/s41591-018-0016-8. View

10.

Reddy A, Zhang J, Davis N, Moffitt A, Love C, Waldrop A . Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. Cell. 2017; 171(2):481-494.e15. PMC: 5659841. DOI: 10.1016/j.cell.2017.09.027. View

11.

Challa-Malladi M, Lieu Y, Califano O, Holmes A, Bhagat G, Murty V . Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell. 2011; 20(6):728-40. PMC: 3660995. DOI: 10.1016/j.ccr.2011.11.006. View

12.

Austen B, Skowronska A, Baker C, Powell J, Gardiner A, Oscier D . Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol. 2007; 25(34):5448-57. DOI: 10.1200/JCO.2007.11.2649. View

13.

Iorio F, Knijnenburg T, Vis D, Bignell G, Menden M, Schubert M . A Landscape of Pharmacogenomic Interactions in Cancer. Cell. 2016; 166(3):740-754. PMC: 4967469. DOI: 10.1016/j.cell.2016.06.017. View

14.

Grzelak L, Roesch F, Vaysse A, Biton A, Legendre R, Porrot F . IRF8 regulates efficacy of therapeutic anti-CD20 monoclonal antibodies. Eur J Immunol. 2022; 52(10):1648-1661. DOI: 10.1002/eji.202250037. View

15.

Morin R, Assouline S, Alcaide M, Mohajeri A, Johnston R, Chong L . Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas. Clin Cancer Res. 2015; 22(9):2290-300. DOI: 10.1158/1078-0432.CCR-15-2123. View